Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03913455 · ClinicalTrials.gov registry record · Phase 2
Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer
A Phase 2 study, sponsored by Shadia Jalal, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT03913455 is a Phase 2 study that has completed, run by Shadia Jalal, MD. The registered enrollment target is 24 participants.
The verdict
NCT03913455, a Phase 2 study, has completed, sponsored by Shadia Jalal, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a phase II, open-label, single arm, single-stage study. Both, chemo-sensitive and chemo-resistant patients will be enrolled and treated with 4 cycles of combination of Guadecitabine and carboplatin
Interventions
- DRUG Carboplatin
- DRUG Guadecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-06-06 |
| Est. Completion | 2022-02-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03913455
The ClinicalTrials.gov registry entry for NCT03913455 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shadia Jalal, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT03913455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03913455 about?
NCT03913455 is a clinical study titled "Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer". This is a phase II, open-label, single arm, single-stage study. Both, chemo-sensitive and chemo-resistant patients will be enrolled and treated with 4 cycles of combination of Guadecitabine and carboplatin
What is the current status of trial NCT03913455?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2019-06-06. Estimated completion is 2022-02-02.
What interventions are being tested in trial NCT03913455?
The interventions under investigation include: Carboplatin (DRUG), Guadecitabine (DRUG).
Who is sponsoring clinical trial NCT03913455?
This trial is sponsored by Shadia Jalal, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.